SCHEMBL2340642

SCHEMBL2340642

CN(C)CC(=O)Nc1cccc(/N=C2\SCC(=O)N2Cc2ccco2)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
POLB P06746 3/20 0.50
LMNA P02545 3/20 0.48
ALDH1A1 P00352 7/20 0.47
MAPT P10636 5/20 0.45
HTT P42858 2/20 0.45
GAA P10253 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 2/20 0.42
TAAR1 Q96RJ0 1/20 0.41
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2340650 1.00 KMT2A (0.53) KMT2AMEN1POLBLMNAALDH1A1
SCHEMBL2079592 0.81 MEN1 (0.60) KMT2AMEN1POLBLMNAALDH1A1
SCHEMBL12775391 0.81 MEN1 (0.60) KMT2AMEN1POLBLMNAALDH1A1
SCHEMBL2079598 0.81 MEN1 (0.60) KMT2AMEN1POLBLMNAALDH1A1
SCHEMBL2080440 0.78 MEN1 (0.58) KMT2AMEN1POLBLMNAALDH1A1
SCHEMBL2080442 0.78 MEN1 (0.58) KMT2AMEN1POLBLMNAALDH1A1
SCHEMBL2332419 0.73 MAPT (0.58) KMT2AMEN1LMNAALDH1A1MAPT
SCHEMBL2332416 0.73 MAPT (0.58) KMT2AMEN1LMNAALDH1A1MAPT
SCHEMBL5673973 0.73 TAAR1 (0.42) KMT2AMEN1POLBLMNAALDH1A1
SCHEMBL2340015 0.72 KMT2A (0.49) KMT2AMEN1POLBLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465882-B1 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-08-24 EP disclosed
US-7115640-B2 Heterocyclic modulators of nuclear receptors X-CEPTOR THERAPEUTICS, INC. (US) 2006-10-03 US disclosed
EP-1465882-A4 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2005-04-06 EP disclosed
EP-1465882-A2 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X-Ceptor Therapeutics, Inc. (US) 2004-10-13 EP disclosed
US-20040180942-A1 Heterocyclic modulators of nuclear receptors X-CEPTOR THERAPEUTICS, INC. 2004-09-16 US disclosed
US-6696473-B2 THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM X-CEPTOR THERAPEUTICS, INC. 2004-02-24 US disclosed
WO-2003060078-A9 HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2004-02-19 WO disclosed
US-20030212111-A1 Heterocyclic modulators of nuclear receptors AKARNA THERAPEUTICS, LTD. (GB) 2003-11-13 US disclosed
WO-2003060078-A2 HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X-CEPTOR THERAPEUTICS, INC. (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180942-A1 Heterocyclic modulators of nuclear receptors NR1H2, NR1H3, NR1H4 KMT2A 2838/4885MEN1 4537/4885POLB 4703/4885
US-20030212111-A1 Heterocyclic modulators of nuclear receptors NR1H2, NR1H3, NR1H4 KMT2A 2838/4885MEN1 4537/4885POLB 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.